Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Macrogenics Inc's Business Segments
Macrogenics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Main
Total Revenue
$ 33
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Main100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Main | $ 33 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- RevenueFromCollaborativeAgreementsMember77.6%
- RevenueFromRoyalityAgreementsMember22.4%
- RevenuesFromLicenseAgreementsMember22.2%
- RevenuesFromCMOAgreementsMember2.4%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| RevenueFromCollaborativeAgreementsMember | $ 25 | 77.6% |
| RevenueFromRoyalityAgreementsMember | $ 7 | 22.4% |
| RevenuesFromLicenseAgreementsMember | $ 7 | 22.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Macrogenics Inc dataset.
Annual Results
Revenue by Product & Service Category -
- RevenuesFromLicenseAgreementsMember95.1%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| RevenuesFromLicenseAgreementsMember | $ 150 | 95.1% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Macrogenics Inc
Macrogenics Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, with additional locations in Virginia and California. The company's mission is to discover and develop innovative therapeutics to address unmet needs in cancer and autoimmune diseases.
Macrogenics Inc. was founded in 2000 by Scott Koenig, who currently serves as the company's President and CEO. The company has since grown to employ approximately 300 people and has raised over $1 billion in funding.
Macrogenics Inc.'s proprietary technology platform is called Dual-Affinity Re-Targeting, or DART, which allows for the development of bi-specific antibodies that can target two different receptors simultaneously. The company's pipeline consists of several bi-specific antibodies in various stages of clinical development.
In oncology, Macrogenics Inc. is focused on developing bi-specific antibodies to target specific cancer cells and to engage and activate immune cells to combat the cancer. Their lead drug candidate in this area is margetuximab, a bi-specific antibody designed to target HER2-expressing breast cancer cells.
In autoimmune diseases, the company is developing bi-specific antibodies that target receptors involved in inflammatory and immune responses. Their lead drug candidate in this area is teplizumab, a bi-specific antibody designed to target T cells and modulate the immune response in type 1 diabetes.
Macrogenics Inc. has established partnerships with several pharmaceutical companies, including Eli Lilly, Incyte, and Janssen Biotech. These partnerships provide the company with additional funding and resources to advance their drug development programs.
In summary, Macrogenics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer and autoimmune diseases using its proprietary DART technology platform. The company has established partnerships with several pharmaceutical companies and has a pipeline of bi-specific antibodies in various stages of clinical development.
Macrogenics Inc. was founded in 2000 by Scott Koenig, who currently serves as the company's President and CEO. The company has since grown to employ approximately 300 people and has raised over $1 billion in funding.
Macrogenics Inc.'s proprietary technology platform is called Dual-Affinity Re-Targeting, or DART, which allows for the development of bi-specific antibodies that can target two different receptors simultaneously. The company's pipeline consists of several bi-specific antibodies in various stages of clinical development.
In oncology, Macrogenics Inc. is focused on developing bi-specific antibodies to target specific cancer cells and to engage and activate immune cells to combat the cancer. Their lead drug candidate in this area is margetuximab, a bi-specific antibody designed to target HER2-expressing breast cancer cells.
In autoimmune diseases, the company is developing bi-specific antibodies that target receptors involved in inflammatory and immune responses. Their lead drug candidate in this area is teplizumab, a bi-specific antibody designed to target T cells and modulate the immune response in type 1 diabetes.
Macrogenics Inc. has established partnerships with several pharmaceutical companies, including Eli Lilly, Incyte, and Janssen Biotech. These partnerships provide the company with additional funding and resources to advance their drug development programs.
In summary, Macrogenics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancer and autoimmune diseases using its proprietary DART technology platform. The company has established partnerships with several pharmaceutical companies and has a pipeline of bi-specific antibodies in various stages of clinical development.
Macrogenics Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics targeting cancer and autoimmune diseases. The company is structured around three primary segments: Clinical Programs, Technology Platforms, and Intellectual Property. Each of these segments plays a pivotal role in the advancement of Macrogenics mission to deliver transformative treatments to patients.
Clinical Programs
Macrogenics Clinical Programs segment encompasses a robust and multifaceted pipeline of product candidates, addressing a variety of cancer types through innovative monoclonal antibodies and bispecific antibody therapies.
- Lead Product Candidate: Margetuximab - Margetuximab is a monoclonal antibody specifically designed for the treatment of HER2-positive breast cancer. It functions by binding to the HER2 protein on cancer cells, enhancing the immune systems capability to fight tumors.
- Monoclonal Antibodies in Development:
- Flotetuzumab: This innovative therapeutic is designed to target and engage immune cells against cancerous cells, specifically aimed at treating hematological malignancies.
- MGA271: Another monoclonal antibody in the pipeline, MGA271 is engineered to target specific tumor-associated antigens, aiming to elicit a strong antitumor immune response.
- MGD013: This product candidate is a program focused on the modulation of the immune checkpoint pathways in solid tumors, potentially improving patient outcomes with precision therapy.
- Advanced Bispecific Antibodies:
- DuoBody-CD3xCD20: This bispecific antibody is engineered to simultaneously bind to CD3 on T cells and CD20 on B cells, providing a mechanism to redirect T-cell activity against B-cell malignancies.
- DuoBody-PD-L1x4-1BB: A combination therapy aiming to enhance T-cell activation in the tumor microenvironment while blocking inhibitory pathways, thus addressing tumor evasion mechanisms.
This clinical pipeline reflects Macrogenics commitment to developing therapies that target specific pathways and mechanisms in cancer progression, addressing unmet medical needs and providing novel solutions for patients.
Technology Platforms
The Technology Platforms segment of Macrogenics represents a core component of the companys drug development strategy, providing the innovative tools necessary for crafting advanced therapeutics.
- DART (Dual-Affinity Re-Targeting) Technology: This proprietary platform allows the design of bispecific antibodies capable of engaging multiple targets, thereby improving therapeutic efficacy by harnessing the body’s immune response against cancer cells.
- Fc Optimization: By modifying the Fc region of antibodies, Macrogenics enhances their pharmacokinetic properties, which include increased potency, extended half-life, and improved safety profiles. This optimization can lead to better patient outcomes through more effective treatment regimens.
- XmAb Technology: This modular platform permits the design of antibodies with customizable features such as enhanced targeting capabilities, tailored effector functions, and prolonged circulation time in the bloodstream. This flexibility supports the development of a wide array of therapeutic candidates.
In addition to these technologies, Macrogenics emphasizes the use of innovative approaches to antibody engineering, providing a competitive edge in the biopharmaceutical landscape.
Intellectual Property
Macrogenics boasts a comprehensive intellectual property portfolio that underpins its technology platforms and product candidates. This segment is critical for safeguarding the companys innovations and maintaining its competitive position in the market.
- Patents: The portfolio includes patents covering proprietary technologies, specific product candidates, and their therapeutic applications. This protection is vital for securing market exclusivity and facilitating future commercialization efforts.
- Licensing Agreements: Macrogenics strategically licenses technologies from other innovative companies to augment its capabilities. Such partnerships enable the company to combine its proprietary platforms with complementary technologies, fostering a more holistic approach to therapeutic development.
In conclusion, Macrogenics Inc. is a cutting-edge biopharmaceutical entity with a strong emphasis on developing innovative therapies for cancer and autoimmune diseases. Its diversified portfolio spans a rich clinical pipeline, advanced technology platforms, and a robust intellectual property framework, collectively driving the companys mission to enhance patient care through groundbreaking therapeutics.
Clinical Programs
Macrogenics Clinical Programs segment encompasses a robust and multifaceted pipeline of product candidates, addressing a variety of cancer types through innovative monoclonal antibodies and bispecific antibody therapies.
- Lead Product Candidate: Margetuximab - Margetuximab is a monoclonal antibody specifically designed for the treatment of HER2-positive breast cancer. It functions by binding to the HER2 protein on cancer cells, enhancing the immune systems capability to fight tumors.
- Monoclonal Antibodies in Development:
- Flotetuzumab: This innovative therapeutic is designed to target and engage immune cells against cancerous cells, specifically aimed at treating hematological malignancies.
- MGA271: Another monoclonal antibody in the pipeline, MGA271 is engineered to target specific tumor-associated antigens, aiming to elicit a strong antitumor immune response.
- MGD013: This product candidate is a program focused on the modulation of the immune checkpoint pathways in solid tumors, potentially improving patient outcomes with precision therapy.
- Advanced Bispecific Antibodies:
- DuoBody-CD3xCD20: This bispecific antibody is engineered to simultaneously bind to CD3 on T cells and CD20 on B cells, providing a mechanism to redirect T-cell activity against B-cell malignancies.
- DuoBody-PD-L1x4-1BB: A combination therapy aiming to enhance T-cell activation in the tumor microenvironment while blocking inhibitory pathways, thus addressing tumor evasion mechanisms.
This clinical pipeline reflects Macrogenics commitment to developing therapies that target specific pathways and mechanisms in cancer progression, addressing unmet medical needs and providing novel solutions for patients.
Technology Platforms
The Technology Platforms segment of Macrogenics represents a core component of the companys drug development strategy, providing the innovative tools necessary for crafting advanced therapeutics.
- DART (Dual-Affinity Re-Targeting) Technology: This proprietary platform allows the design of bispecific antibodies capable of engaging multiple targets, thereby improving therapeutic efficacy by harnessing the body’s immune response against cancer cells.
- Fc Optimization: By modifying the Fc region of antibodies, Macrogenics enhances their pharmacokinetic properties, which include increased potency, extended half-life, and improved safety profiles. This optimization can lead to better patient outcomes through more effective treatment regimens.
- XmAb Technology: This modular platform permits the design of antibodies with customizable features such as enhanced targeting capabilities, tailored effector functions, and prolonged circulation time in the bloodstream. This flexibility supports the development of a wide array of therapeutic candidates.
In addition to these technologies, Macrogenics emphasizes the use of innovative approaches to antibody engineering, providing a competitive edge in the biopharmaceutical landscape.
Intellectual Property
Macrogenics boasts a comprehensive intellectual property portfolio that underpins its technology platforms and product candidates. This segment is critical for safeguarding the companys innovations and maintaining its competitive position in the market.
- Patents: The portfolio includes patents covering proprietary technologies, specific product candidates, and their therapeutic applications. This protection is vital for securing market exclusivity and facilitating future commercialization efforts.
- Licensing Agreements: Macrogenics strategically licenses technologies from other innovative companies to augment its capabilities. Such partnerships enable the company to combine its proprietary platforms with complementary technologies, fostering a more holistic approach to therapeutic development.
In conclusion, Macrogenics Inc. is a cutting-edge biopharmaceutical entity with a strong emphasis on developing innovative therapies for cancer and autoimmune diseases. Its diversified portfolio spans a rich clinical pipeline, advanced technology platforms, and a robust intellectual property framework, collectively driving the companys mission to enhance patient care through groundbreaking therapeutics.